---
title: "Akebia Therapeutics Unveils New Vafseo Clinical Data at ASN Kidney Week 2025"
description: "Akebia Therapeutics Inc. will present new clinical data on Vafseo® (vadadustat) at the ASN Kidney Week 2025 from November 5-9 in Houston, Texas. The presentation will include results from real-world e"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261879749.md"
published_at: "2025-10-20T12:08:53.000Z"
---

# Akebia Therapeutics Unveils New Vafseo Clinical Data at ASN Kidney Week 2025

> Akebia Therapeutics Inc. will present new clinical data on Vafseo® (vadadustat) at the ASN Kidney Week 2025 from November 5-9 in Houston, Texas. The presentation will include results from real-world evidence studies, focusing on the clinical benefits and dosing of Vafseo. Highlights include an oral session on the analysis of deaths and hospitalizations in CKD patients and four posters on dosing recommendations and safety. The studies aim to provide insights into the effectiveness of vadadustat compared to darbepoetin.

Akebia Therapeutics Inc. announced that it will present new data regarding Vafseo® (vadadustat) at the American Society of Nephrology Kidney Week 2025, scheduled for November 5-9, 2025, in Houston, Texas. The company will share results from ongoing real-world evidence studies and provide insights into the clinical benefits and dosing of Vafseo. Presentations include an oral session on the win-odds analysis of deaths and hospitalizations in patients taking vadadustat or darbepoetin alfa for chronic kidney disease (CKD)-related anemia undergoing dialysis, to be delivered by Dr. Glenn M. Chertow. Additionally, Akebia will present four posters on dosing recommendations, the safety of three times weekly vadadustat, and comparative responsiveness of vadadustat versus darbepoetin. The results of these studies are scheduled to be presented at the upcoming conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9548340-en) on October 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [AKBA.US - Akebia Therap](https://longbridge.com/en/quote/AKBA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit | Akebia Therapeutics highlighted its commercial priorities and pipeline at the Guggenheim Emerging Outlook Biotech Summit | [Link](https://longbridge.com/en/news/275778572.md) |
| Akebia Therapeutics Reports Vadadustat Reduces Death and Hospitalization in Dialysis Patients | Akebia Therapeutics Inc. reported that vadadustat significantly reduces death and hospitalization rates in dialysis pati | [Link](https://longbridge.com/en/news/264743235.md) |
| Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit | Maze Therapeutics (NASDAQ: MAZE) is advancing a genetics-driven drug development approach, focusing on kidney and metabo | [Link](https://longbridge.com/en/news/275972996.md) |
| Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says | Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says | [Link](https://longbridge.com/en/news/275490601.md) |
| National Donor Day Spotlight: DaVita Patient Care Technician Donates Kidney | On National Donor Day, DaVita highlights Holly, a patient care technician who donated her kidney. After her husband Hest | [Link](https://longbridge.com/en/news/275937358.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.